Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 16;15(1):453.
doi: 10.1186/s12917-019-2189-x.

RNA disruption indicates CHOP therapy efficacy in canine lymphoma

Amadeo M Parissenti  1   2 , Laura B Pritzker  3 , Baoqing Guo  4 , Rashmi Narendrula  4 , Shirly Xiaohui Wang  3 , Lin Laura Lin  3 , Jingchun Pei  3 , Karolina Skowronski  5 , Dorothee Bienzle  6 , J Paul Woods  5 , Kenneth P H Pritzker  3 , Brenda L Coomber  7
Affiliations

RNA disruption indicates CHOP therapy efficacy in canine lymphoma

Amadeo M Parissenti et al. BMC Vet Res. .

Abstract

Background: Assessment of the efficacy of a multi-agent chemotherapy protocol in which cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are administered in canine lymphoma is generally performed by physical measurement of lymph node diameter. However, no consistent correlation has been made with prognostic indicators and the length or absence of clinical remission based on lymph node size. RNA disruption measured mid-therapy has been correlated with increased disease-free survival in recent studies of human cancer and was assessed in this study of canine lymphoma patients. Fine needle aspirate samples were taken before treatment and at weeks 3, 6, and 11 of CHOP therapy. RNA was isolated from these samples and assessed using an Agilent Bioanalyzer. RNA disruption assay (RDA) analysis was performed on the data from the resulting electropherograms.

Results: An increased RNA disruption index (RDI) score was significantly associated with improved progression-free survival.

Conclusions: Predicting the risk of early relapse during chemotherapy could benefit veterinary patients by reducing ineffective treatment and could allow veterinary oncologists to switch earlier to a more effective drug regimen.

Keywords: Chemotherapy treatment response; RNA analysis.

PubMed Disclaimer

Conflict of interest statement

LP, RN, SW, LL, JP and KP are/were employees of Rna Diagnostics. BG, KP, and AP are shareholders in Rna Diagnostics.

Figures

Fig. 1
Fig. 1
RNA disruption during CHOP therapy for dogs separated by immunophenotype. RNA disruption during CHOP therapy for dogs separated by immunophenotype A) dogs that had B cell lymphoma (n = 19) and B) dogs that had T cell lymphoma (n = 4). Five dogs were found to have inadequate samples at all time-points and were therefore not included; 13 dogs did not have their tumour immunophenotype determined. Each line represents an individual animal
Fig. 2
Fig. 2
Maximum RDI Values and Response to CHOP Therapy. Maximum RDI values were determined for each dog for all FNA samples taken during therapy. RDI values were grouped by relapse status; relapsed after CHOP therapy, relapsed during CHOP therapy, or progressive disease. RDI values were higher in dogs that responded to treatment (and had a relapse after the completion of CHOP therapy) compared with dogs that had a relapse during therapy (Mann-Whitney test p = .04)
Fig. 3
Fig. 3
Kaplan-Meier plots of Progression-Free Survival. Kaplan-Meier plots depicting differences in PFS over time between patients with A) average RDI values > 0.6 and ≤ 0.6 and B) maximum RDI values > 0.7 and ≤ 0.7. Hazard ratios associated with the RDI values are listed in the plots. Differences between survival curves are statistically significant (log-rank test p = 0.006 for average RDI and log rank test p = 0.006 for maximum RDI)
See this image and copyright information in PMC

References

    1. Marconato L, Gelain ME, Comazzi S. The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol. 2013;31(1):1–9. doi: 10.1002/hon.2017. - DOI - PubMed
    1. Flory AB, Rassnick KM, Erb HN, Garrett LD, Northrup NC, Selting KA, Phillips BS, Locke JE, Chretin JD. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007) J Am Vet Med Assoc. 2011;238(4):501–506. doi: 10.2460/javma.238.4.501. - DOI - PubMed
    1. Rassnick KM, Bailey DB, Malone EK, Intile JL, Kiselow MA, Flory AB, Barlow LL, Balkman CE, Barnard SM, Waite AH. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. Vet Comp Oncol. 2010;8(4):243–253. doi: 10.1111/j.1476-5829.2010.00224.x. - DOI - PubMed
    1. Vail DM, Michels GM, Khanna C, Selting KA, London CA. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2010;8(1):28–37. doi: 10.1111/j.1476-5829.2009.00200.x. - DOI - PubMed
    1. Zandvliet M. Canine lymphoma: a review. The Vet Q. 2016;36(2):76–104. doi: 10.1080/01652176.2016.1152633. - DOI - PubMed

MeSH terms